Anti-CGRP monoclonal antibodies are the first migraine drugs designed from neuropeptide biology, offering high efficacy but facing cost and access challenges in real-world practice.
First migraine-specific drugsAnti-CGRP antibodies are the first medications designed from migraine neuropeptide biology, rather than borrowed from other conditions
What the researchers found
Anti-CGRP monoclonal antibodies represent a paradigm shift in migraine treatment — the first drugs designed specifically around migraine pathophysiology. These drugs target calcitonin gene-related peptide (CGRP), a neuropeptide that plays a central role in causing migraine attacks. The review concludes that anti-CGRP mAbs are highly effective but face real-world challenges: high cost, limited long-term experience, and the need for multidisciplinary teams to identify which patients will benefit most.
The review emphasizes that proper patient selection and cost-effective prescribing strategies are essential as these drugs move from clinical trials into routine practice.
Why it matters
For decades, migraine treatments were borrowed from other conditions — blood pressure drugs, antidepressants, anti-seizure medications. Anti-CGRP antibodies are the first migraine drugs designed from the ground up based on understanding the neuropeptide that triggers attacks. This represents one of the most successful examples of peptide biology leading directly to a new drug class, and it has transformed care for millions of chronic migraine patients who failed older treatments.
The numbers in context
CGRP identified as key migraine neuropeptide · multiple anti-CGRP mAbs developed · high efficacy reported · high cost identified as barrier · multidisciplinary teams recommended
How the study worked
Narrative review of the literature on anti-CGRP monoclonal antibodies for migraine, covering pathophysiology, drug mechanisms, clinical evidence, practical management considerations, and cost-effectiveness.
Who was studied
Review covering migraine patients, particularly those eligible for anti-CGRP monoclonal antibody therapy
What this study cannot tell us
Narrative review without systematic methodology. Mostly summarizes existing knowledge without new data. Limited discussion of specific efficacy numbers or head-to-head comparisons. Published in 2022 — newer data on long-term safety and real-world effectiveness has since accumulated.
How to read the evidence
Strong — while this is a narrative review, it synthesizes evidence from multiple randomized controlled trials that led to FDA approval of anti-CGRP antibodies. The clinical effectiveness of these drugs is well-established through rigorous phase III trials. The review itself provides clinical guidance rather than new data.
When this study was published
Published in 2022. The anti-CGRP field has continued to evolve with longer-term safety data, real-world studies, and the introduction of oral CGRP antagonists (gepants). The core information about drug mechanisms and efficacy remains current.
The bigger picture
The CGRP story is one of the greatest successes of translational peptide research. From discovering CGRP's role in migraine in the 1980s to FDA-approved antibodies in the 2010s, it took decades — but the result transformed a field where patients had few options. The anti-CGRP class (erenumab, fremanezumab, galcanezumab, eptinezumab) now represents a multi-billion dollar market. More broadly, CGRP-targeting illustrates how understanding a single neuropeptide's role in disease can lead to an entirely new therapeutic approach.
Questions still open
- What are the long-term safety implications of chronically blocking CGRP, which has protective roles in cardiovascular and wound healing processes?
- How should clinicians decide between anti-CGRP antibodies and newer CGRP receptor antagonists (gepants) for individual patients?
- Can anti-CGRP therapies be made cost-effective enough for widespread use in healthcare systems with limited budgets?
Common questions
What is CGRP and why does blocking it help migraine?
Who should consider anti-CGRP antibody treatment for migraine?
Read the original research
Treatment of migraine with monoclonal antibodies.
Expert opinion on biological therapy, 22(6), 707-716
Citation
Serra López-Matencio, José María; Gago-Veiga, Ana Beatriz; Gómez, Manuel; Alañón Plaza, Estefanía; Mejía, Gina Paola; González-Gay, Miguel Ángel; Castañeda, Santos. (2022). Treatment of migraine with monoclonal antibodies.. Expert opinion on biological therapy, 22(6), 707-716. https://doi.org/10.1080/14712598.2022.2072207